Revatio 20 mg film coated tablets ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 1 |
86. Pulmonary arterial hypertension
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-003978-41-Outside-EU/EEA (EUCTR) | 13/10/2016 | Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension | A Phase 3, Multi-center, Open label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension | Pulmonary arterial hypertension MedDRA version: 19.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Revatio 10 mg/ml powder for oral suspension Product Name: Revatio POS Product Code: G04BE03 INN or Proposed INN: 171 Other descriptive name: SILDENAFIL CITRATE Trade Name: Revatio 20 mg film coated tablets Product Name: Revatio Tablets Product Code: G04BE03 INN or Proposed INN: 171 Other descriptive name: SILDENAFIL CITRATE | Pfizer, Inc. | NULL | NA | Female: yes Male: yes | 6 | Phase 3 | Japan |